Boston Mountain Biotech NSF Final Presentation
•Download as PPTX, PDF•
1 like•1,932 views
Recommended
More Related Content
Viewers also liked
Viewers also liked (7)
Similar to Boston Mountain Biotech NSF Final Presentation
Similar to Boston Mountain Biotech NSF Final Presentation (20)
More from Stanford University
More from Stanford University (20)
Recently uploaded
Recently uploaded (20)
Boston Mountain Biotech NSF Final Presentation
- 1. National Science Foundation I-Corps Program May 23, 2012 www.bostonmountainbiotech.com
- 2. Team Members Ellen Brune, Entrepreneurial Lead • PhD Candidate in Chemical Engineering • Doctoral Academy Fellow • Graduate Certificate in Entrepreneurship Robert Beitle P.E., Principle Investigator • Faculty in the Department of Chemical Engineering • Bioprocess Design and Development Beverly Graham, Industrial Mentor • Pel-Freez Biologicals • 20+ years experience in Sales and Marketing in the biotech industry
- 3. The Biopharmaceutical Industry • Typically spends $8B every year on protein-based drug purification per drug • Interested in a solution to minimize their COGS and improve their margin
- 4. $50 Billion Dollar Protein Therapeutic Market $24 Billion Dollar Cell Line Sales $1.4 Billion Dollar E. coli Target
- 5. Our Technology – Cells Make Less Trash DNA DNA Lotus Lotus Database Provisional Patent Filed March13, 2012 Application #: 61/610298
- 6. Key Partners Key Activities Key Resources Value Product Customer Relationship Customer Channels Customer Segments Cost Segments Revenue Segments Our First Business Canvas UA incubator UAMS (GMP) Bioproximity Innovate AR Parkside Financial Complete MVPs based on customer feedback Laboratory GMP (?) Scientists Startup ($) IP (exclusive) R&D for the MVPs People Provide E. coli cell line(s) for simplified downstream processing (purification) Web Sales Trade Shows Direct Sales Tech Support Consultative Segmented and niche market Direct Sales Royalties Commercial Licensing
- 7. Customer Contacts • Refine possible customer segments • Food • Industrial Enzymes • Biopharmaceuticals • Diagnostics • Reagents • Test hypothesis statements • Composition of Minimum Viable Product • Value Proposition • Revenue model structure • Establish relationships with potential partners and customers Customer Contact 101 total
- 8. Lotus $8.2M/year savings per drug $0 $5 $10 $15 $20 $25 $30 Millions Total COGS Comparison $24M $16M Application of Technology
- 9. • Discussion focused on three drug pipelines • Our IMAC prototype is moderately useful • Ion exchange friendly cell line would be disruptive technology • Confirmed certain aspects of revenue model • Viability of custom cell line construction as a RS • Royalty payment of 5% is reasonable assumption
- 10. Competitor Comparison Industry Standard Invitrogen (LifeTech) OneShot ™ Boston Mountain Biotech Estimated Required Purification Steps 6+ 3 Purification Cost Savings NONE 20 - 70% * Average Commercial Cost Savings per Year per Drug $0 $8.2M Customized Versions -- Yes Annual License Cost per Drug $75,000 + 3-5% of revenue Negotiable Pricing (average $240,000) Lotus
- 11. Revenue and distribution channels Academics / Not-for Profits Contract Manufacturer Biopharma Start-up Large Pharma Payments Material Transfer Actions Contract Sale License Agreement
- 12. Customer Segments • Commercial Institutions: • Primary Market • $1.4B (Globally) • License and Revenue sharing agreements • Academic Labs: • Secondary Market • Increase Visibility of Tech • $140 M (North America) • Product Sales
- 13. Key Partners Key Activities Key Resources Value Product Customer Relationship Customer Channels Customer Segments Cost Segments Revenue Segments Our Final Business Canvas • Large Pharma • Protein CMOs • Academic Labs • Drug Discovery Groups • Enzyme Manufacturers • Diagnostics Manufacturers • Technical Support • Consultation • Direct Sales • Website Sales • Cell Lines • Direct Sales • Royalties and Licensing Fees • Database Access Fee • Simplify Protein Purification • Increase Yield and Throughput • Decrease COGS and Process Waste • UA Facilities • Scientists and Engineers • Exclusive IP • Startup Cash • Cost to complete two MVPs • Salaries for Scientists and Engineers • Exclusive IP License Fee • UA • Business Incubator • GMP Facility at UAMS • Walton College • State • Innovate AR • Fund for AR Future • Parkside Financial • Production of Cell Lines • R&D for Cell Lines and Database
- 14. + $50,000
- 15. Corporate Growth Roadmap • Signed an exclusive license with the Univ. of Arkansas • Finalize commercial prototype • Sign CDAs with Merck and CSL Behring • Begin commercial prototype pilot testing • Start writing SBIR grants • Finalize acquiring state-supported funding
- 16. National Science Foundation I-Corps Program May 23, 2012 www.bostonmountainbiotech.com
- 17. Canvas evolution slides start here
- 18. Our first canvas (original idea, with mistakes) 4 - University of Arkansas - Separatome based E. coli purification platform UA incubator UAMS (GMP) Bioproximity Innovate AR Parkside Financial Complete MVPs based on customer feedback Laboratory GMP (?) Scientists Startup ($) IP (exclusive) R&D for the MVPs People Provide E. coli cell line(s) for simplified downstream processing (purification) Web Sales Trade Shows Direct Sales Tech Support Consultative Segmented and niche market Direct Sales Royalties Commercial Licensing
- 19. University of Arkansas: Separatome based E. coli purification platform Provide E. coli cell line(s) for simplified downstream processing (purification) Segmented and niche market Biopharma Biotechnolog y Food Tech Support Consultative Web Sales Trade Shows Sales Force Complete MVPs based on customer feedback Laboratory (GMP ?) Scientists Startup ($) UA incubator UAMS (GMP) Bioproximity Value driven R&D for the MVPs People Licensing (implicit – academic) (written – industry)
- 20. University of Arkansas: Separatome based E. coli purification platform Provide E. coli cell line(s) for simplified downstream processing (purification) Simplify Protein Purification Increase Yield Increase Throughput Decrease Cost Segmented and niche market Biopharma Biotechnology Food Tech Support Consultative Web Sales Trade Shows Direct Sales Complete MVPs based on customer feedback Laboratory GMP (?) Scientists Startup ($) IP (exclusive license) UA incubator UAMS (GMP) ASTA Bioproximity Innovate AR Parkside Financial R&D for the MVPs People Direct Sales Royalties Commercial Licensing Database License Protein CMOs Drug Discovery Research Groups Industrial Enzyme Manufacturers Academic Protein Research Labs
- 21. University of Arkansas: Separatome based E. coli purification platform Simplify Protein Purification Increase Yield Increase Throughput Decrease COGS Decrease Waste Tech Support Consultative Web Sales Direct Sales Provide MVP to Customer R&D Production Support Laboratory GMP Scientists Startup $ IP (exclusive license) UA incubator UAMS (GMP) ASTA Fund for Arkansas Future Bioproximity Innovate AR Parkside Financial U of A Business Plan Competitions ($$$) R&D for the MVPs People IP License Direct Sales Royalties Commercial Licensing Database License Protein CMOs Drug Discovery Research Groups Diagnostic Research Groups Industrial Enzyme Manufacturers Academic Protein Research Labs
- 22. University of Arkansas: Separatome based E. coli purification platform Simplify Protein Purification Increase Yield Increase Throughput Decrease COGS Decrease Waste Tech Support Consultative Web Sales Direct Sales R&D Production Support Laboratory GMP Scientists Startup $ IP (exclusive license) UA incubator UAMS (GMP) ASTA Fund for Arkansas Future Bioproximity Innovate AR Parkside Financial U of A Business Plan Competitions ($$$) R&D for the MVPs People IP License Direct Sales Royalties Commercial Licensing Database License Protein CMOs Drug Discovery Research Groups Diagnostic Research Groups Industrial Enzyme Manufacturers Academic Protein Research Labs Large Pharma
- 23. Present canvas (after five iterations) • Large Pharma • Protein CMOs • Academic Labs • Drug Discovery Groups • Enzyme Manufacturers • Diagnostics Manufacturers • Technical Support • Consultation • Direct Sales • Website Sales • Cell Lines • Direct Sales • Royalties and Licensing Fees • Database Access Fee • Simplify Protein Purification • Increase Yield and Throughput • Decrease COGS and Process Waste • UA Facilities • Scientists and Engineers • Exclusive IP • Startup Cash • Cost to complete two MVPs • Salaries for Scientists and Engineers • Exclusive IP License Fee • UA • Business Incubator • GMP Facility at UAMS • Walton College • State • Innovate AR • Fund for AR Future • Parkside Financial • Production of Cell Lines • R&D for Cell Lines and Database 4 - University of Arkansas - Separatome based E. coli purification platform
- 24. Backup material
- 26. Market
- 27. What kind of business are we building? • IP based • Data on E. coli sepratome • E. coli cell lines that improve chromatography • License of an E. coli expression platform • Technical Services/Support
- 28. Disruptive Innovation • Generate a new markets • Reduction in entry cost barrier • Simplified purification process • Access existing markets • Large Manufacturers • Existing FDA approved drugs • Pre-FDA drugs in the pipeline • Sticky Technology • Cell line tied to FDA approval
- 29. Hypothesis Statements • On-going • A cell line “tool kit” would be beneficial • Protein manufacturers have control over cell line selection • Added by teaching team • Local council with biotech IP experience is available • BMB revenue model is valid (royalties, fees) • Speaking with biotech entrepreneurs will provide valued advice 4 - University of Arkansas - Separatome based E. coli purification platform
- 30. Our first canvas (original idea, with mistakes) Unclear value proposition Definition, not who Unrealistic channel Random list of hopefuls + current 4 - University of Arkansas - Separatome based E. coli purification platform
- 31. Contact Method • Almost all of our contacts were done via conference • Video • Audio • Multimedia • Cold call strategy adapted slightly • Set stage for conversation • Two or three of us on each call • Also used survey tools • LinkedIn / Surveymonkey • Respondents not included in contact count IM sent email to contact (or PI) Appointment set, short summary sent electronically Conversation Follow-up 4 - University of Arkansas - Separatome based E. coli purification platform
- 32. Lotus IMAC 0-10mM 10-50mM 50-100mM 100-200mM 200-500mM • Less background proteins are present by choosing appropriate strain • Five cell lines, each line has different set of background proteins “removed” • Cell line used to express target protein (e.g. insulin)
Editor's Notes
- DNA NOT GENES!!
- BioMarin is currently NOT a profitable company because of their COGS
- Neulasta 4th quarter sales of $918M $3,672M yearly sales 3-5% is $110-180M based on sales not on revenue
- While we have looked at one company in the market, lets take a broader look at the entire market. The US protein expression kit market was estimated at 200 M in 2008 and had experienced 20% growth The global market for cells and cells lines was over 1.4B in 2011 and experiencing 10% growth